View metadata, citation and similar papers at core.ac.uk
brought to you by CORE
provided by Open Research Exeter

1 # Neuromuscular electrical stimulation prevents muscle disuse atrophy during
2 leg immobilisation in humans

3

4 Marlou L. Dirks[1], Benjamin T. Wall[1], Tim Snijders[1], Chris L.P. Ottenbros[2], Lex B. Verdijk[1] and
5 Luc J.C. van Loon[1]

6

7 *[1]NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht,*
8 *the Netherlands*
9 *[2]Department of Surgery, Maastricht University Medical Centre+, Maastricht, the Netherlands*

10

11 **Address for correspondence:**
12 Prof. L.J.C. van Loon, PhD
13 Department of Human Movement Sciences
14 Maastricht University Medical Centre
15 P.O. Box 616
16 6200 MD, Maastricht, the Netherlands
17 Phone: +31 43 3881397
18 Email: L.vanLoon@maastrichtuniversity.nl
19

20 **Short title:** NMES prevents short-term muscle disuse atrophy
21 **Keywords:** NMES, immobilisation, skeletal muscle, disuse atrophy
22 **Clinical trial registration:** NCT01513486
23 **Word count**: 5611

Abstract

Short periods of muscle disuse, due to illness or injury, result in substantial skeletal muscle atrophy. Recently we have shown that a single session of neuromuscular electrical stimulation (NMES) increases muscle protein synthesis rates. **Aim:** To investigate the capacity for daily NMES to attenuate muscle atrophy during short-term muscle disuse. **Methods**: Twenty-four healthy, young (23±1 y) males participated in the present study. Volunteers were subjected to 5 days of one-legged knee immobilisation with (NMES; *n*=12) or without (CON; *n*=12) supervised NMES sessions (40 min sessions, twice daily). Two days prior to and immediately after the immobilisation period, CT-scans and single leg one-Repetition Maximum (1RM) strength tests were performed to assess quadriceps muscle cross-sectional area (CSA) and leg muscle strength, respectively. Furthermore, muscle biopsies were taken to assess muscle fibre CSA, satellite cell content and mRNA and protein expression of selected genes. **Results:** In CON, immobilisation reduced quadriceps CSA by 3.5±0.5% (P<0.0001) and muscle strength by 9±2% (P<0.05). In contrast, no significant muscle loss was detected following immobilisation in NMES although strength declined by 7±3% (P<0.05). Muscle MAFbx and MuRF1 mRNA expression increased following immobilisation in CON (P<0.001 and P=0.07, respectively) whereas levels either declined (P<0.01) or did not change in NMES, respectively. Immobilisation led to an increase in muscle myostatin mRNA expression in CON (P<0.05) but remained unchanged in NMES. **Conclusion:** During short-term disuse, NMES represents an effective interventional strategy to prevent the loss of muscle mass, but it does not allow preservation of muscle strength. NMES during disuse may be of important clinical relevance in both health and disease.

46 **Abbreviations**

47 CT, Computed Tomography; CSA, Cross Sectional Area; DEXA, Dual Energy X-Ray
48 Absorptiometry; FAK, Focal Adhesion Kinase; FOXO1, Forkhead box protein O1; FT, fibre
49 typing; LAT1, Large Neutral Amino Acid Transporter 1; MAFBx, Muscle Atrophy F-
50 box/Atrogen-1; mTOR, mammalian target of rapamycin; MuRF1, Muscle RING-finger protein-1;
51 NMES, Neuromuscular Electrical Stimulation; PAT1, Proton-coupled amino acid transporter 1;
52 PBS, phosphate-buffered saline; P70S6K, P70S6 kinase; RT, room temperature; SC, satellite cell;
53 1RM, 1-Repetition Maximum.

54 **Introduction**

55 Situations such as the recovery from illness or injury require otherwise healthy individuals to
56 undergo short periods of bed-rest or limb immobilisation. Under these circumstances there is a
57 rapid loss of skeletal muscle mass [1-3] that leads to reduced functional capacity [1-4], loss of
58 muscle strength [5], impaired insulin sensitivity [6], a decline in basal metabolic rate [7, 8], and a
59 concomitant increase in body fat mass [9-11]. As a consequence, the extent of disuse atrophy that
60 occurs due to illness or injury has previously been identified as an important predictor of the
61 duration of hospitalization and subsequent rehabilitation [12].

62 During periods of disuse, muscle atrophy occurs as a consequence of an imbalance between muscle
63 protein synthesis and breakdown rates. Previous studies, employing either 10-14 days of bed rest
64 [10, 13] or 2-6 weeks of limb immobilisation [2, 14-16] as models of disuse, have demonstrated
65 impairments in both fasting and post-prandial muscle protein synthesis rates without any
66 discernible changes in muscle protein breakdown [13, 17]. Maintaining a certain minimal level of
67 physical activity during periods of muscle disuse can offset such impairments in post-absorptive
68 or post-prandial muscle protein synthesis rates [11, 18] and, as such, attenuate muscle tissue loss
69 [19, 20]. Unfortunately, in many clinical situations physical activity is temporarily not feasible or
70 simply impossible and, thus, surrogates should be sought to alleviate muscle disuse atrophy.

71 Neuromuscular electrical stimulation (NMES) offers an attractive alternative way to allow muscle
72 contraction, thereby acting as a surrogate for habitual physical activity during periods of muscle
73 disuse due to illness or injury. Recently, we applied contemporary stable isotope methodology
74 with repeated muscle biopsy sampling to demonstrate that a single session of NMES increases
75 muscle protein synthesis rates for several hours *in vivo* in men [21]. Moreover, self-administered
76 NMES has previously been shown to maintain muscle protein synthesis rates during long term

77 recovery from tibia fracture [14], and clinically applied NMES has shown beneficial effects on
78 skeletal muscle function in patients recovering from surgery [22, 23] or suffering from severe
79 cardiac complications [24, 25]. However, to date, the capacity of supervised NMES as an
80 interventional strategy to counteract the loss of muscle mass and strength during a short period of
81 disuse remains to be established. This may be of important clinical relevance as the loss of muscle
82 mass and strength during short periods of bed rest or immobilisation following illness or injury are
83 believed to delay subsequent recovery and likely contribute substantially to the loss of muscle
84 mass with aging [26, 27].
85 In the present study we investigate the efficacy of NMES as a means to attenuate skeletal muscle
86 disuse atrophy. We hypothesized that a twice daily supervised NMES program could preserve
87 skeletal muscle mass and attenuate the loss of muscle strength during a 5 day period of leg
88 immobilisation. We assessed changes in muscle mass following 5 days of one-legged knee
89 immobilisation using a full leg cast in 24 healthy young men with or without twice daily supervised
90 NMES sessions. Muscle mass was assessed at a limb level using CT and DEXA scans, whereas
91 muscle biopsies were obtained prior to and immediately after immobilisation to assess changes in
92 muscle fibre type characteristics and relevant myocellular signalling.

Materials and Methods

Subjects

A total of 24 healthy young males (age: 23±1 y; body mass: 76±2 kg; body mass index [BMI] 22±1 kg/m^2) were included in the present study which was approved by the Medical Ethical Committee of the Maastricht University Medical Centre+ in accordance with the Declaration of Helsinki. Prior to the study, subjects completed a routine medical screening and general health questionnaire to ensure their suitability to take part. Exclusion criteria were: BMI below 18.5 or above 30 kg/m^2; any back, knee or shoulder complaints which may interfere with the use of crutches; type 2 diabetes mellitus (determined by HbA1c-values >7.0%); any family history of thrombosis; and/or severe cardiac problems. Furthermore, subjects who had performed structured and prolonged resistance type exercise training during the 6 months prior to the study were also excluded. All subjects were informed of the nature and possible risks of the experimental procedures, before their written informed consent was obtained. During screening, an estimation of one-repetition maximum (1RM) single leg knee extension strength (Technogym, Rotterdam, the Netherlands) was made using the multiple repetitions testing procedure [28].

Study design

After inclusion, subjects were randomly allocated into either the control (CON; *n*=12) or the neuromuscular electrical stimulation (NMES; *n*=12) group. The experimental protocol is depicted in **Figure 1.** Both groups underwent a 5 day period of muscle disuse induced via one-legged knee immobilisation by way of a full leg cast, either with (NMES group) or without (CON group) NMES performed twice daily under supervision at home. The leg to be immobilized was randomized and counter-balanced between left and right. On two separate test days, 48 h before

117 and immediately after the immobilisation period, single slice computed tomography (CT) scans
118 were performed at the mid-thigh of both legs, whole body dual energy x-ray absorptiometry
119 (DEXA) scans were taken, leg volume was measured by anthropometry [29], a single muscle
120 biopsy and venous blood sample were collected, and one-legged knee extension strength (1RM)
121 was assessed.
122
123 *Muscle mass and function*
124 Forty eight h prior to, and immediately after the immobilisation period, subjects visited the
125 laboratory in the fasted state for 2 identical test days (i.e. test days 1 and 2). During the test days,
126 several measurements of muscle mass and function were performed. First, anatomical cross-
127 sectional area (CSA) of the quadriceps muscle and whole thigh were assessed via a single slice CT
128 scan (Philips Brilliance 64, Philips Medical Systems, Best, the Netherlands). The scanning
129 characteristics were as follows: 120 kV, 300 mA, rotation time of 0.75 s, and a field of view of
130 500 mm. While the subjects were lying supine, legs extended and their feet secured, a 3 mm thick
131 axial image was taken 15 cm proximal to the top of the patella. On test day 1, the precise scanning
132 position was marked with semi-permanent ink for replication on test day 2. CT-scans were
133 analysed for the CSA of the whole thigh muscle as well as the quadriceps by manual tracing using
134 ImageJ software (version 1.46d, National Institute of Health, Maryland, USA)[30]. Thereafter,
135 body composition and bone mineral content were measured via DEXA-scan (Hologic, Discovery
136 A, QDR Series, Bradford, MA, USA). Whole-body and regional lean mass were determined using
137 the system's software package Apex version 2.3. Leg volume of both legs was also assessed by
138 anthropometry as described previously [29]. Maximal calf circumference of both legs was
139 measured as part of the measurements to determine leg volume. Maximum strength was evaluated

140 for each leg separately by one-repetition maximum (1RM) strength tests on a leg extension
141 machine (Technogym, Rotterdam, the Netherlands). The estimations obtained during the screening
142 visit were used to determine 1RM as described previously [31].

143

144 *Blood and muscle sampling*

145 During test day 1, fasting venous blood samples were collected to determine basal plasma glucose
146 and insulin concentrations. Blood (10 mL) was collected into EDTA-containing tubes and directly
147 centrifuged at 1,000g for 10 min at 4°C. Aliquots of plasma were immediately frozen in liquid
148 nitrogen and stored at -80°C until further analysis. Plasma glucose concentrations (Glucose HK
149 CP, ABX Diagnostics, ref. A11A01667, Montpellier, France) were analysed with a COBAS
150 FARA semi-automatic analyser (Roche, Basel, Switzerland). Plasma insulin concentrations were
151 determined by radioimmunoassay (Millipore, ref. HI-14K , Billerica, MA, USA). Additionally,
152 during test day 1 and 2, a single muscle biopsy sample was collected from the leg previously
153 selected for immobilisation. After local anaesthesia was induced, percutaneous needle biopsy
154 samples were collected from the *vastus lateralis* muscle, approximately 15 cm above the patella
155 [32]. Any visible non-muscle tissue was removed immediately, and part of the biopsy sample was
156 embedded in Tissue-Tec (Sakura Finetek, Zoeterwoude, the Netherlands) before being frozen in
157 liquid nitrogen-cooled isopentane, while another part was immediately frozen in liquid nitrogen.
158 Muscle samples were subsequently stored at -80°C until further analyses.

159

160 *Leg immobilisation*

161 Forty eight h following test day 1, a full leg cast (randomized and counterbalanced for left and
162 right legs) was applied in the plaster room of the Academic Hospital in Maastricht at 8:00 on the
163 first day of the immobilisation period. The leg cast extended from ~5 cm above the ankle until ~25

164 cm above the patella (i.e. approximately halfway up the upper leg). The cast was set so the knee
165 joint was placed at a ~30 degree angle of flexion to prevent subjects from performing weight-
166 bearing activities with the casted leg. The immobilisation period always comprised 3 week days
167 and 2 weekend days. Additionally, for subjects assigned to the NMES group, placement of the
168 electrodes for NMES was determined prior to fitting the cast (described below) and a small
169 'window' (a rectangle of approximately 12 × 6 cm) was cut in the cast ~5 cm above the knee.
170 Following the removal of this window, the section of cast was placed back from where it was
171 removed and bandaged firmly in place. Subjects were given crutches and instructed on their correct
172 usage before being provided with transportation home. Application of the cast signified the
173 beginning of the immobilisation period which continued for 5 d, after which the cast was removed
174 at 8.00 at the plaster room immediately prior to performing test day 2.
175
176 *Neuromuscular electrical stimulation*
177 For subjects allocated to the NMES group, two NMES sessions were performed each day at the
178 subjects' home for the duration of the 5 day immobilisation period (i.e. 10 sessions in total).
179 Neuromuscular electrical stimulation sessions were performed in the morning (7.00-12.00) and
180 afternoon (13.00-18.00), with a minimum of 4 h between sessions. During each session, with the
181 subject lying supine with a pillow placed under the knee to obviate the flexion angle, the window
182 was removed from the cast and electrodes were placed on the distal part at the muscle belly of the
183 *m. rectus femoris* and the *m. vastus lateralis*, and at the inguinal area of both muscles. The position
184 of the electrodes was re-marked each day with semi-permanent ink to ensure that location of the
185 electrodes was not altered between sessions.

186 Stimulation was provided by an Enraf Nonius TensMed S84 stimulation device (Enraf Nonius,
187 Rotterdam, the Netherlands) and 4, 2 mm-thick, self-adhesive electrodes (50 x 50 mm; Enraf
188 Nonius), discharging biphasic symmetric rectangular-wave pulses. The NMES protocol consisted
189 of a warm-up phase (5 min, 5 Hz, 250 μs), a stimulation period (30 min, 100 Hz, 400 μs, 5 s on
190 (0.75 s rise, 3.5 s contraction, 0.75 s fall) and 10 s off), and a cooling-down phase (5 min, 5 Hz,
191 250 μs). Subjects set the intensity of the stimulation to a level at which full contractions of *m.*
192 *quadriceps femoris* were visible and palpable, and the heel began to slightly lift. This protocol was
193 based on our previous work [21] demonstrating an acute increase in muscle protein synthesis
194 following a single bout of NMES and selected due to previous work using high-frequency (>60
195 Hz), high pulse duration (>250 μs) NMES [33, 34]. Researchers encouraged subjects to increase
196 the intensity of the stimulation during each subsequent session to provide a 'progressive' stimulus.
197
198 *Dietary intake*
199 On the evening prior to both test days subjects received a standardized meal containing 2900 kJ
200 providing 51 Energy% (En%) as carbohydrate, 32 En% as fat, and 17 En% as protein. Subjects
201 completed weighted dietary intake records for the 5 day duration of the immobilisation period as
202 well as on a separate consecutive 5 day occasion before the immobilisation period. The same 5
203 days of the week were selected for both recording periods. Dietary intake records were analysed
204 with DieetInzicht software, based on NEVO table 2011.
205
206 *Muscle analyses*
207 The portion of the muscle biopsies frozen and mounted in Tissue-Tek was cut into 5μm thick
208 cryosections using a cryostat at -20°C. Pre and post samples from one control and one NMES
209 subject were mounted together on uncoated, pre-cleaned glass slides. Care was taken to correctly

210 align the samples for cross-sectional fibre analyses. Muscle biopsies were stained for muscle fibre
211 typing (FT) and satellite cell (SC) content as described in detail previously [35]. In short, slides
212 were incubated with primary antibodies directed against myosin heavy chain (MHC)-I (A4.840,
213 dilution 1:25; Developmental Studies Hybridoma Bank, Iowa City, IA), laminin (polyclonal rabbit
214 anti-laminin, dilution 1:50; Sigma, Zwijndrecht, the Netherlands) and CD56 (dilution 1:40; BD
215 Biosciences, San Jose, CA). The following appropriate secondary antibodies were applied: goat
216 anti-mouse IgM AlexaFluor555, goat anti-rabbit IgG AlexaFluor647, and Streptavidin Alexa 488
217 (dilution 1:500, 1:400, and 1:200, respectively; Molecular Probes, Invitrogen, Breda, the
218 Netherlands). Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, 0.238 μM;
219 Molecular Probes). Images were captured at 10x magnification with a fluorescent microscope
220 equipped with an automatic stage, and analysed using ImageJ software (version 1.46r, National
221 Institute of Health [30]). Mean numbers of 184±17 and 220±22 muscle fibres were analysed in the
222 biopsy samples collected pre and post immobilisation, respectively.

223 The portion of the muscle biopsy sample immediately frozen in liquid nitrogen was used to
224 determine mRNA and protein expression of several target genes as described previously [36]. In
225 short, total RNA was isolated from 10-20 mg of frozen muscle tissue, which was then quantified
226 spectrophotometrically. Thereafter, RNA purity was determined and cDNA synthesis was
227 performed, and Taqman PCR was carried out as reported previously using 18S as a housekeeping
228 gene [37]. Taqman primer/probe sets were obtained from Applied Biosystems (Foster City, USA)
229 for the following genes of interest: mammalian target of rapamycin (mTOR), P70S6 kinase
230 (P70S6K), myogenic factor 4 (myogenin), MyoD, myostatin, Atrogen-1/Muscle Atrophy F-box
231 (MAFbx), Muscle RING-finger protein-1 (MuRF1), Forkhead box protein O1 (FOXO1), Focal
232 Adhesion Kinase (FAK), large neutral amino acid transporter 1 (LAT1) and Proton-coupled amino

233 acid transporter 1 (PAT1). C*t* values of the target genes were normalized to C*t* values of the internal
234 control 18S, and final results were calculated as relative expression against the standard curve.
235 Muscle samples (~40 mg) for Western blotting analyses were analysed as described previously
236 [37]. The antibodies used in this study were anti Myostatin (52 kD; dilution 1:500; rabbit
237 polyclonal IgG; Santa Cruz sc-6885-R), anti MyoD (37 kD; dilution 1:1000; rabbit polyclonal IgG;
238 Santa Cruz sc-760), anti Myogenin (34 kD; dilution 1:500; rabbit polyclonal IgG; Santa Cruz sc-
239 576) and anti α-actin (42 kD; dilution 1:160.000, mouse monoclonal IgM; Sigma A2172).
240

241 *Statistics*
242 All data are expressed as mean±standard error of the mean (SEM). Baseline characteristics
243 between groups were compared by means of an independent samples t-test. Pre- versus post-
244 intervention data were analysed using repeated-measures ANOVA with time (pre vs. post) as
245 within-subjects factor and treatment (CON vs. NMES) as between-subjects factor. Pearson's
246 Correlation Coefficient was used to test for significant correlations. For the muscle fibre analysis,
247 fibre type (type I vs. type II) was added to the repeated-measures ANOVA as a within-subjects
248 factor. In case of a significant interaction, paired t tests were performed to determine time effects
249 within groups or within type I or II fibres and independent t tests for group differences in the pre-
250 and post-intervention values. Statistical significance was set at $P<0.05$. All calculations were
251 performed using SPSS version 20.0 (Chicago, IL, USA).

252 **Results**

253

254 *Subjects*

255 Subjects' characteristics are provided in **Table 1**. No differences between the control (CON) and

256 neuromuscular electrical stimulation (NMES) group were observed for any of the parameters.

257

258 *Dietary intake*

259 During the 5 days of immobilisation the daily energy intake averaged 8.5±0.7 and 8.7±0.6 MJ per

260 day in the CON and NMES group, respectively, with average daily protein intakes of 1.01±0.04

261 and 1.00±0.08 g/kg body weight/day. For both energy intake and protein intake, no significant

262 interaction effects were found.

263

264 *Neuromuscular electrical stimulation*

265 The intensity of the NMES intervention for subjects in the NMES group averaged 20.8±1.6 mA

266 during the first session and was progressively increased to 42.2±3.7 mA in the final session. The

267 average NMES intensity across all sessions and all subjects was 30.6±2.2 mA.

268

269 *Muscle mass*

270 For quadriceps muscle CSA, a significant time*treatment interaction was observed in the

271 immobilized leg (**Figure 2**; P<0.001**)**. Quadriceps CSA in the CON group had decreased by

272 3.5±0.5% (from 7504±342 to 7238±324 mm^2; P<0.001), whereas in the NMES group no

273 significant decrease in quadriceps CSA was detected (from 7740±259 to 7675±254 mm^2: P=0.07).

274 In agreement, a significant time*treatment interaction (P<0.001) was also observed for changes in

275 CSA of the whole-thigh muscle, which showed a 3.7±0.6% decrease in the CON group (P<0.001),
276 with no changes in the NMES group (-0.5±0.4%: P=0.192). In the non-immobilized leg,
277 quadriceps and thigh muscle CSA did not show any changes following 5 days of immobilisation
278 in both the CON and NMES group.
279 In line with the data on muscle CSA, a significant time*treatment interaction was observed for leg
280 lean mass (P<0.05). Subjects in the CON group lost on average 147±72 g of muscle tissue in the
281 immobilized leg, representing 1.4±0.7% loss of leg muscle tissue (P=0.066). In contrast, the
282 NMES group showed an increase of 209±82 g (1.9±0.7%) in the immobilized leg after 5 days of
283 immobilisation (P<0.05). No changes over time in leg lean mass were detected in the non-
284 immobilized leg of subjects in the CON and NMES group (P>0.05).
285 For leg volume and calf circumference, no changes over time (time effect, P>0.05) or between
286 groups (interaction effect, P>0.05) were observed.
287 Scatter plots for correlations between NMES intensity and key outcome measures are presented as
288 supplemental information in **Figure 5**. No significant correlations were found between the NMES
289 intensity and delta quadriceps CSA (**Figure 5A**), delta muscle strength (**Figure 5B)**, and delta leg
290 lean mass (**Figure 5C)**, respectively.
291
292 *Muscle strength*
293 For muscle strength, a significant main effect of time (P=0.001) was detected in the immobilized
294 leg such that one-legged 1RM declined by 9.0±2.2% (from 77.9±3.9 to 71.1±4.1 kg) and 6.5±3.2%
295 (from 78.3±4.5 to 72.9±4.4 kg) in the CON and NMES groups, respectively, with no differences
296 between groups. Muscle strength in the non-immobilized leg increased in both groups (time effect,

297 *P*<0.05); from 78.8±4.4 to 81.5±4.9 kg in the CON group and from 76.9±3.1 to 81.9±3.4 kg in the
298 NMES group.
299
300 *Muscle fibre characteristics*
301 Muscle fibre characteristics are displayed in **Table 2**. Before the intervention, no significant
302 difference was observed in type I and type II muscle fibre CSA between groups. A significant
303 time*treatment*fibre type interaction was observed for muscle fibre CSA (*P*<0.001). Separate
304 analyses showed no significant change in both type I and type II muscle fibre CSA in the CON
305 group after immobilisation. In contrast, we observed a significant increase in type II muscle fibre
306 CSA in the NMES group over time (from 5885 ± 426 to 6412 ± 586 μm^2; *P*<0.05), whereas in
307 type I fibres no time effect was observed (*P*>0.05). Fibre distribution showed no differences at
308 baseline between groups, and did not change over time in both groups (*P*>0.05).
309 For myonuclear domain size, a significant time*treatment*fibre type interaction was observed
310 (*P*<0.05) and an overall effect of fibre type (*P*<0.001), with larger myonuclear domain sizes in
311 type II vs. type I fibres in both the CON and NMES group. No changes in type I myonuclear
312 domain size were found (*P*>0.05), while a significant time*treatment interaction was observed in
313 type II fibres (*P*<0.05) caused by a greater myonuclear domain in the NMES vs. CON group after
314 immobilisation.
315 At baseline, no differences in SC content were observed between groups (*P*>0.05). In addition, no
316 changes over time were found for type I and type II SC content expressed per muscle fibre, per
317 millimetre squared, or as a percentage of the total number of myonuclei (*P*>0.05 for all three
318 parameters).
319

mRNA and protein expression

Figure 3 and **4** display the relative expression in skeletal muscle mRNA of selected genes of interest in the CON and NMES group, two days prior to and immediately following 5 days of one-legged knee-immobilisation. No differences in mRNA expression of selected genes were observed between CON and NMES at baseline. For muscle myostatin mRNA expression, a significant time*treatment interaction was observed (**Figure 3A**; $P<0.05$). Separate analysis showed a 68% increase following immobilisation in the CON group ($P<0.05$), whereas a trend for a decline was observed in the NMES group ($P=0.075$). For muscle mRNA expression of MyoD (**Figure 3C)** and myogenin **(Figure 3E)** a significant increase was observed over time ($P<0.05$ and $P<0.01$, respectively), with no differences between groups.

A significant time*treatment interaction was observed for the mRNA expression of muscle MAFbx (**Figure 4A**; $P<0.001$) and MuRF1 (**Figure 4B**; $P<0.05$). MAFBx mRNA expression was upregulated in the CON group (48%; $P<0.001$), whereas in the NMES group a decline was observed (35%, $P<0.05$). MuRF1 mRNA expression tended to increase in the CON group (56%, $P=0.066$), while no change over time was observed in the NMES group ($P>0.05$). No significant changes occurred over time or between groups in the muscle mRNA expression of FOXO1 (**Figure 4C**), mTOR (**Figure 4E**) or FAK (**Figure 4D**). A significant time*treatment interaction was observed for the muscle mRNA expression of P70S6K (**Figure 4F**; $P<0.05$), with an 18% upregulation following immobilisation in the CON group ($P<0.01$), whereas no change was observed in the NMES group ($P>0.05$). Muscle mRNA expression of the amino acid transporters LAT1/SLC (**Figure 4G**) and PAT1 (**Figure 4H)** had significantly increased following immobilisation (both $P<0.05$), with no differences between groups.

342 Protein expression of myostatin, myoD and myogenin are presented in **Figure 3**. For both
343 myostatin and MyoD, no changes in protein expression were observed (both $P>0.05$). Myogenin
344 protein expression tended to increase following immobilisation ($P=0.054$) with no differences
345 between groups ($P=0.122$ for time*treatment interaction).
346

347 **Discussion**

348 In the present study, we demonstrated that neuromuscular electrical stimulation (NMES) prevented
349 skeletal muscle atrophy to occur during 5 days of one-legged knee immobilisation. However,
350 NMES could not rescue the loss of muscle strength during this short period of disuse. Moreover,
351 we report that the molecular changes associated with muscle disuse atrophy can largely be
352 prevented by the daily application of NMES.

353 Skeletal muscle disuse leads to a loss of muscle mass and strength and is accompanied by
354 numerous negative health consequences [1-4, 6-11]. Based on previous studies, the rate of muscle
355 loss during experimental lower limb immobilisation is approximately 0.5% per day [27, 38].
356 However, this loss does not appear to be linear with higher rates of muscle loss occurring during
357 the first few days of disuse [39]. In the present study we report that merely 5 days of one-legged
358 knee immobilisation significantly decreased quadriceps muscle cross sectional area by 3.5% in a
359 group of healthy young males (**Figure 2**; CON group), representing ~150 g of muscle tissue lost
360 from the immobilized leg. When translating our observations of muscle loss in a single limb to a
361 whole-body level, assuming that 60% of whole-body muscle loss occurs in the lower limbs,
362 patients could lose as much as 1 kg of muscle tissue during 5 days of bed rest [5, 40]. This is
363 consistent with previous studies investigating the impact of 10 days of bed-rest [13, 40].
364 Furthermore, the 5 days of leg immobilisation also resulted in a substantial 9.0±2.2% decline in
365 leg strength. Clearly, these data demonstrate the impact of short periods of muscle disuse on
366 muscle mass and strength and underline the clinical relevance to develop effective interventional
367 strategies to attenuate muscle disuse atrophy and associated negative health consequences.

368 The use of NMES has been proposed as an interventional strategy to alleviate muscle loss in a
369 variety of clinical conditions [14, 22-25]. Recently, we showed that a single NMES session

370 stimulates muscle protein synthesis *in vivo* in men [21]. In the current study, we investigated
371 whether the application of daily NMES could attenuate the loss of muscle mass during a short
372 period of muscle disuse. Strikingly, the application of supervised NMES performed twice daily on
373 the immobilized leg entirely prevented any disuse atrophy (**Figure 2**), with no measurable loss of
374 muscle observed in the NMES group (-0.8±0.4%; $P>0.05$). Given the inherent variability of the
375 measurement of muscle fibre size [41], we were unable to detect specific muscle fibre atrophy
376 following only 5 days of disuse in the control group (**Table 2**). However, we did detect a small but
377 significant increase in type II muscle fibre size following immobilisation in the group receiving
378 NMES. These data suggest that high-frequency NMES may exert its protective effect on skeletal
379 muscle disuse atrophy predominantly through the recruitment of type II muscle fibres. This is of
380 significant relevance as muscle loss due to more prolonged disuse [42, 43] and/or aging [44, 45]
381 has been attributed to specific type II muscle fibre atrophy [41]. It is important to view the present
382 data in the context of the potential clinical benefits of applying NMES to preserve muscle mass
383 during relatively short periods of muscle disuse. Previously, NMES has generally been applied
384 during rehabilitation [46, 47], when muscle mass has already been lost and has to be regained.
385 However, in the present study we clearly demonstrate the relevance of applying NMES *during* a
386 period of disuse or bed rest to prevent muscle tissue loss.
387 Muscle disuse atrophy is generally accompanied by a substantial decline in muscle strength and
388 impairments in functional capacity [1-3]. Previous studies performing one-legged knee
389 immobilisation have reported a decline in muscle strength ranging from 0.4 [48] to 4.2% per day
390 [49] with an average muscle strength loss of ~1.3% per day [27]. In the present study, we report
391 that 5 days of limb immobilisation resulted in a 9.0% loss of leg muscle strength (representing an
392 average daily loss of 1.8% per day). Consistent with earlier reports [4, 49, 50], we show a greater

393 relative decline in muscle strength when compared to the loss of muscle mass. This is in agreement
394 with previous suggestions that neuromuscular deconditioning during the early stages of training or
395 disuse is mainly responsible for the rapid changes in muscle strength [51, 52]. This also explains
396 why the decline in muscle strength in the control group was only partially rescued with NMES (-
397 6.5±3.2%). We speculate that the application of NMES will likely further attenuate muscle
398 strength loss during more prolonged periods of muscle disuse, when muscle mass loss becomes
399 the key determinant of the decline in muscle strength. In agreement, previous work assessing the
400 impact of prolonged NMES training has been shown to effectively increase muscle strength in
401 healthy young subjects [33, 34], in CHD patients [53] and in patients suffering from septic shock
402 [54].
403 Aside from assessing the impact of NMES on muscle mass and strength during a period of disuse,
404 we also investigated some of the myocellular mechanisms that may be responsible for the NMES
405 mediated prevention of muscle mass loss during immobilisation. Skeletal muscle satellite cells
406 (SCs) are essential for repair, maintenance and growth of myofibres [55-57]. Moreover, we have
407 previously reported that type II fibre specific atrophy associated with aging [58] and spinal cord
408 injury [59] is also accompanied by a decline in SC content in these fibres. In the present study, we
409 hypothesized that a better maintenance of muscle SC content in the NMES group contributes to
410 the preservation of muscle mass. However, short term immobilisation did not alter SC content in
411 either type I or II fibres in either the control or NMES group (**Table 2**). As such, the present data
412 suggest that changes in SC content are not instrumental in the early development of disuse atrophy,
413 nor the NMES mediated prevention of muscle loss. However, it cannot be ruled out that the rate
414 of SC proliferation may be of more relevance during muscle atrophy (or NMES mediated
415 prevention of muscle loss) observed over a more prolonged period of disuse [60]. Furthermore, we

416 determined the mRNA and protein expression of key signalling proteins thought to be important
417 in the regulation of muscle maintenance. Myostatin is regarded as a negative regulator of muscle
418 mass *in vivo* [61, 62], primarily by inhibiting myogenesis [63, 64] via its inhibitory action on the
419 myogenic regulatory factors [65], notably MyoD and myogenin [66, 67]. Consistent with the
420 proposed role of myostatin, we report an increased mRNA expression in the CON group that was
421 prevented in the NMES group (**Figure 3**). Moreover, the significant increase in the mRNA
422 expression of MyoD and myogenin seemed to be larger in the NMES group but was observed in
423 both groups, while this did not result in an increased muscle protein expression (**Figure 3**).
424 Collectively these data are consistent with a role for myostatin in the NMES mediated maintenance
425 of muscle mass during disuse.

426 Increased rates of muscle protein breakdown have been suggested to play a role in short term (<10
427 days) muscle disuse atrophy [27, 68]. Muscle protein breakdown in humans is thought to be
428 regulated primarily by the ubiquitin-proteasome pathway, with key roles for the ubiquitin ligases
429 MAFbx and MuRF1 [69, 70], and their upstream transcription factor FOXO1 [71]. In accordance,
430 in the present study we report that both MAFbx and MuRF1 mRNA expression increase with
431 immobilisation (**Figure 4**). Strikingly, these effects were prevented in the NMES group,
432 suggesting that NMES may also help to preserve muscle mass during disuse by preventing an
433 increase in muscle protein breakdown.

434 In the present study we applied NMES to the quadriceps only. This muscle group is particularly
435 susceptible to muscle loss during whole body disuse [5] and is functionally important to allow
436 proper performance of daily living activities. From a clinical perspective, it could be speculated
437 that multiple muscle groups should be targeted with NMES to ensure muscle mass maintenance
438 during whole body disuse. Although extending the use of NMES to multiple muscle groups could

439 introduce practical constraints (e.g. skin irritation, antagonistic contractions, time constraints),
440 optimizing such protocols will allow (more) effective clinical use of NMES. Given the role of
441 skeletal muscle mass in metabolic homeostasis, muscle preservation during disuse would likely
442 have a positive impact on preserving both metabolic health [72] and functional capacity.
443 The present study clearly demonstrates that merely a few days of disuse will lead to substantial
444 loss of muscle mass and strength. Furthermore, NMES is identified as an effective interventional
445 strategy to preserve muscle mass during such short periods of disuse. These data are of important
446 clinical relevance as hospitalization following acute illness or injury is generally accompanied by
447 a hospital stay of ~6 days [73]. The loss of muscle mass and strength during such short (successive)
448 periods of muscle disuse impairs functional capacity and hinders the subsequent rehabilitation
449 upon discharge. In fact, it is now much speculated that the development of sarcopenia in the older
450 population is, at least partly, attributed to the muscle loss that is experienced during short,
451 successive periods of muscle disuse due to illness or injury occurring over the latter 2-3 decades
452 of our lifespan [26, 39]. The use of NMES could also be of particular relevance to other patient
453 groups and populations suffering from muscle atrophy, such as athletes recovering from injury
454 [74], mechanically ventilated patients [54], spinal cord injured subjects [59], and post-surgery
455 patients [23]. Preventing or attenuating the loss of muscle mass and strength during limb
456 immobilisation or bed rest likely minimizes the burden of muscle disuse, shortens hospital stay,
457 and facilitates subsequent rehabilitation in both health and disease.
458 In conclusion, NMES represents an effective interventional strategy to prevent the loss of muscle
459 mass *during* short periods of muscle disuse. This is likely attributed to a stimulation of muscle
460 protein synthesis and suppression of muscle protein breakdown. NMES forms a feasible strategy

461 to prevent muscle loss and support subsequent rehabilitation during short periods of muscle disuse

462 due to illness or injury.

Acknowledgements

The authors greatly acknowledge the cooperation and enthusiasm of the staff in the casting room of the Academic Hospital Maastricht. Furthermore, the assistance of Mellanie Geijen during the data collection, and the technical assistance by Joan M.G. Senden and Antoine Zorenc are very much appreciated.

Conflict of interest

No conflicts of interest are declared by the authors.

Author contributions

The study was performed at Maastricht University, Maastricht, the Netherlands. M.L.D., B.T.W. and L.J.C.v.L. did the conception and design of the study; M.L.D., B.T.W., T.S. and C.L.P.O. performed the experiments; M.L.D. and B.T.W. analysed the data; M.L.D., B.T.W., T.S., L.B.V. and L.J.C.v.L. interpreted the results; M.L.D. drafted the manuscript; M.L.D., B.T.W., T.S., C.L.P.O., L.B.V. and L.J.C.v.L. edited and revised the manuscript. All authors approved the final version of the manuscript.

References

1. Deitrick, J.E., The effect of immobilization on metabolic and physiological functions of normal men. *Bull N Y Acad Med*, 1948. **24**(6): p. 364-75.
2. Gibson, J.N., et al., Decrease in human quadriceps muscle protein turnover consequent upon leg immobilization. *Clin Sci (Lond)*, 1987. **72**(4): p. 503-9.
3. Ingemann-Hansen, T. and J. Halkjaer-Kristensen, Computerized tomographic determination of human thigh components. The effects of immobilization in plaster and subsequent physical training. *Scand J Rehabil Med*, 1980. **12**(1): p. 27-31.
4. White, M.J., C.T. Davies, and P. Brooksby, The effects of short-term voluntary immobilization on the contractile properties of the human triceps surae. *Q J Exp Physiol*, 1984. **69**(4): p. 685-91.
5. LeBlanc, A.D., et al., Regional changes in muscle mass following 17 weeks of bed rest. *J Appl Physiol (1985)*, 1992. **73**(5): p. 2172-8.
6. Stuart, C.A., et al., Bed-rest-induced insulin resistance occurs primarily in muscle. *Metabolism*, 1988. **37**(8): p. 802-6.
7. Haruna, Y., et al., Decremental reset in basal metabolism during 20-days bed rest. *Acta Physiol Scand Suppl*, 1994. **616**: p. 43-9.
8. Tzankoff, S.P. and A.H. Norris, Effect of muscle mass decrease on age-related BMR changes. *J Appl Physiol Respir Environ Exerc Physiol*, 1977. **43**(6): p. 1001-6.
9. Brooks, N., et al., Resistance training and timed essential amino acids protect against the loss of muscle mass and strength during 28 days of bed rest and energy deficit. *J Appl Physiol (1985)*, 2008. **105**(1): p. 241-8.
10. Ferrando, A.A., et al., Prolonged bed rest decreases skeletal muscle and whole body protein synthesis. *Am J Physiol*, 1996. **270**(4 Pt 1): p. E627-33.
11. Ferrando, A.A., et al., Resistance exercise maintains skeletal muscle protein synthesis during bed rest. *J Appl Physiol (1985)*, 1997. **82**(3): p. 807-10.
12. Christensen, T., T. Bendix, and H. Kehlet, Fatigue and cardiorespiratory function following abdominal surgery. *The British journal of surgery*, 1982. **69**(7): p. 417-9.
13. Kortebein, P., et al., Effect of 10 days of bed rest on skeletal muscle in healthy older adults. *JAMA*, 2007. **297**(16): p. 1772-4.
14. Gibson, J.N., K. Smith, and M.J. Rennie, Prevention of disuse muscle atrophy by means of electrical stimulation: maintenance of protein synthesis. *Lancet*, 1988. **2**(8614): p. 767-70.
15. Glover, E.I., et al., Immobilization induces anabolic resistance in human myofibrillar protein synthesis with low and high dose amino acid infusion. *J Physiol*, 2008. **586**(Pt 24): p. 6049-61.
16. de Boer, M.D., et al., The temporal responses of protein synthesis, gene expression and cell signalling in human quadriceps muscle and patellar tendon to disuse. *J Physiol*, 2007. **585**(Pt 1): p. 241-51.
17. Symons, T.B., et al., Artificial gravity maintains skeletal muscle protein synthesis during 21 days of simulated microgravity. *J Appl Physiol (1985)*, 2009. **107**(1): p. 34-8.
18. Burd, N.A., S.H. Gorissen, and L.J. van Loon, Anabolic resistance of muscle protein synthesis with aging. *Exerc Sport Sci Rev*, 2013. **41**(3): p. 169-73.
19. Oates, B.R., et al., Low-volume resistance exercise attenuates the decline in strength and muscle mass associated with immobilization. *Muscle Nerve*, 2010. **42**(4): p. 539-46.
20. Kawakami, Y., et al., Changes in muscle size, architecture, and neural activation after 20 days of bed rest with and without resistance exercise. *European journal of applied physiology*, 2001. **84**(1-2): p. 7-12.
21. Wall, B.T., et al., Neuromuscular electrical stimulation increases muscle protein synthesis in elderly type 2 diabetic men. *Am J Physiol Endocrinol Metab*, 2012. **303**(5): p. E614-23.

22. Snyder-Mackler, L., et al., Use of electrical stimulation to enhance recovery of quadriceps femoris muscle force production in patients following anterior cruciate ligament reconstruction. *Physical therapy*, 1994. **74**(10): p. 901-7.
23. Vinge, O., et al., Effect of transcutaneous electrical muscle stimulation on postoperative muscle mass and protein synthesis. *Br J Surg*, 1996. **83**(3): p. 360-3.
24. Banerjee, P., et al., Prolonged electrical muscle stimulation exercise improves strength, peak VO2, and exercise capacity in patients with stable chronic heart failure. *Journal of cardiac failure*, 2009. **15**(4): p. 319-26.
25. Vivodtzev, I., et al., Improvement in quadriceps strength and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD. *Chest*, 2006. **129**(6): p. 1540-8.
26. English, K.L. and D. Paddon-Jones, Protecting muscle mass and function in older adults during bed rest. *Curr Opin Clin Nutr Metab Care*, 2010. **13**(1): p. 34-9.
27. Wall, B.T. and L.J. van Loon, Nutritional strategies to attenuate muscle disuse atrophy. *Nutr Rev*, 2013. **71**(4): p. 195-208.
28. Mayhew, J.L., et al., Muscular endurance repetitions to predict bench press strength in men of different training levels. *J Sports Med Phys Fitness*, 1995. **35**(2): p. 108-13.
29. Jones, P.R. and J. Pearson, Anthropometric determination of leg fat and muscle plus bone volumes in young male and female adults. *The Journal of physiology*, 1969. **204**(2): p. 63P-66P.
30. Strandberg, S., et al., Reliability of computed tomography measurements in assessment of thigh muscle cross-sectional area and attenuation. *BMC Med Imaging*, 2010. **10**: p. 18.
31. Verdijk, L.B., et al., One-repetition maximum strength test represents a valid means to assess leg strength in vivo in humans. *J Sports Sci*, 2009. **27**(1): p. 59-68.
32. Bergstrom, J., Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. *Scand J Clin Lab Invest*, 1975. **35**(7): p. 609-16.
33. Gondin, J., et al., Neuromuscular electrical stimulation training induces atypical adaptations of the human skeletal muscle phenotype: a functional and proteomic analysis. *J Appl Physiol (1985)*, 2011. **110**(2): p. 433-50.
34. Maffiuletti, N.A., et al., Neuromuscular adaptations to electrostimulation resistance training. *Am J Phys Med Rehabil*, 2006. **85**(2): p. 167-75.
35. Leenders, M., et al., Elderly men and women benefit equally from prolonged resistance-type exercise training. *J Gerontol A Biol Sci Med Sci*, 2013. **68**(7): p. 769-79.
36. Wall, B.T., et al., Substantial skeletal muscle loss occurs during only 5 days of disuse. *Acta Physiol (Oxf)*, 2013.
37. Wall, B.T., et al., Disuse impairs the muscle protein synthetic response to protein ingestion in healthy men. *J Clin Endocrinol Metab*, 2013.
38. Phillips, S.M., E.I. Glover, and M.J. Rennie, Alterations of protein turnover underlying disuse atrophy in human skeletal muscle. *Journal of applied physiology*, 2009. **107**(3): p. 645-54.
39. Wall, B.T., M.L. Dirks, and L.J. van Loon, Skeletal muscle atrophy during short-term disuse: Implications for age-related sarcopenia. *Ageing Res Rev*, 2013.
40. Ferrando, A.A., et al., EAA supplementation to increase nitrogen intake improves muscle function during bed rest in the elderly. *Clin Nutr*, 2010. **29**(1): p. 18-23.
41. Nilwik, R., et al., The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. *Experimental gerontology*, 2013.
42. Bamman, M.M., et al., Impact of resistance exercise during bed rest on skeletal muscle sarcopenia and myosin isoform distribution. *J Appl Physiol (1985)*, 1998. **84**(1): p. 157-63.
43. Yasuda, N., et al., Sex-based differences in skeletal muscle function and morphology with short-term limb immobilization. *J Appl Physiol*, 2005. **99**(3): p. 1085-92.

44. Verdijk, L.B., et al., Protein supplementation before and after exercise does not further augment skeletal muscle hypertrophy after resistance training in elderly men. *The American journal of clinical nutrition*, 2009. **89**(2): p. 608-16.
45. Tieland, M., et al., Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind, placebo-controlled trial. *Journal of the American Medical Directors Association*, 2012. **13**(8): p. 720-6.
46. Harris, S., et al., A randomised study of home-based electrical stimulation of the legs and conventional bicycle exercise training for patients with chronic heart failure. *Eur Heart J*, 2003. **24**(9): p. 871-8.
47. Neder, J.A., et al., Home based neuromuscular stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). *Thorax*, 2002. **57**((4)): p. 333-7.
48. Seynnes, O.R., et al., Early structural adaptations to unloading in the human calf muscles. *Acta physiologica*, 2008. **193**(3): p. 265-74.
49. Thom, J.M., et al., Effect of 10-day cast immobilization on sarcoplasmic reticulum calcium regulation in humans. *Acta physiologica Scandinavica*, 2001. **172**(2): p. 141-7.
50. Jones, S.W., et al., Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. *FASEB J*, 2004. **18**(9): p. 1025-7.
51. Clark, B.C. and T.M. Manini, Sarcopenia =/= dynapenia. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 2008. **63**(8): p. 829-34.
52. Enoka, R.M., *Neuromechanics of Human Movement*. Vol. 4. 2008: Human Kinetics.
53. Quittan, M., et al., Strength improvement of knee extensor muscles in patients with chronic heart failure by neuromuscular electrical stimulation. *Artif Organs*, 1999. **23**(5): p. 432-5.
54. Rodriguez, P.O., et al., Muscle weakness in septic patients requiring mechanical ventilation: protective effect of transcutaneous neuromuscular electrical stimulation. *J Crit Care*, 2012. **27**(3): p. 319 e1-8.
55. Mauro, A., Satellite cell of skeletal muscle fibers. *J Biophys Biochem Cytol*, 1961. **9**: p. 493-5.
56. Moss, F.P. and C.P. Leblond, Nature of dividing nuclei in skeletal muscle of growing rats. *J Cell Biol*, 1970. **44**(2): p. 459-62.
57. Moss, F.P. and C.P. Leblond, Satellite cells as the source of nuclei in muscles of growing rats. *Anat Rec*, 1971. **170**(4): p. 421-35.
58. Verdijk, L.B., et al., Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly. *Am J Physiol Endocrinol Metab*, 2007. **292**(1): p. E151-7.
59. Verdijk, L.B., et al., Reduced satellite cell numbers with spinal cord injury and aging in humans. *Med Sci Sports Exerc*, 2012. **44**(12): p. 2322-30.
60. Guo, B.S., et al., Electrical stimulation influences satellite cell proliferation and apoptosis in unloading-induced muscle atrophy in mice. *PloS one*, 2012. **7**(1): p. e30348.
61. McPherron, A.C., A.M. Lawler, and S.J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. *Nature*, 1997. **387**(6628): p. 83-90.
62. Elliott, B., et al., The central role of myostatin in skeletal muscle and whole body homeostasis. *Acta Physiol (Oxf)*, 2012. **205**(3): p. 324-40.
63. Lee, S.J. and A.C. McPherron, Regulation of myostatin activity and muscle growth. *Proceedings of the National Academy of Sciences of the United States of America*, 2001. **98**(16): p. 9306-11.
64. Thomas, M., et al., Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. *The Journal of biological chemistry*, 2000. **275**(51): p. 40235-43.
65. Amthor, H., et al., The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. *Dev Biol*, 2002. **251**(2): p. 241-57.

66. Sabourin, L.A. and M.A. Rudnicki, The molecular regulation of myogenesis. *Clinical genetics*, 2000. **57**(1): p. 16-25.
67. Snijders, T., L.B. Verdijk, and L.J. van Loon, The impact of sarcopenia and exercise training on skeletal muscle satellite cells. *Ageing research reviews*, 2009. **8**(4): p. 328-38.
68. Tesch, P.A., et al., Skeletal muscle proteolysis in response to short-term unloading in humans. *J Appl Physiol (1985)*, 2008. **105**(3): p. 902-6.
69. Bodine, S.C., et al., Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science*, 2001. **294**(5547): p. 1704-8.
70. Gomes, M.D., et al., Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proceedings of the National Academy of Sciences of the United States of America*, 2001. **98**(25): p. 14440-5.
71. Murton, A.J., D. Constantin, and P.L. Greenhaff, The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy. *Biochimica et biophysica acta*, 2008. **1782**(12): p. 730-43.
72. Nair, K.S., Aging muscle. *Am J Clin Nutr*, 2005. **81**(5): p. 953-63.
73. Fisher, S.R., et al., Early ambulation and length of stay in older adults hospitalized for acute illness. *Arch Intern Med*, 2010. **170**(21): p. 1942-3.
74. Khalid, M., A. Brannigan, and T. Burke, Calf muscle wasting after tibial shaft fracture. *Br J Sports Med*, 2006. **40**(6): p. 552-3.
75. Matthews, D.R., et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*, 1985. **28**(7): p. 412-9.

Tables

Table 1: Subjects' characteristics

	CON (*n*=12)	**NMES (*n*=12)**
Age (y)	22 ± 1	23 ± 1
Body mass (kg)	74.4 ± 3.5	77.7 ± 2.2
Height (m)	1.84 ± 0.03	1.84 ± 0.02
BMI (kg/m^2)	21.9 ± 1.0	23.1 ± 0.7
Leg volume (L)	8.23 ± 0.50	8.15 ± 0.30
Glucose (mmol/L)	5.01 ± 0.11	5.08 ± 0.07
Insulin (mU/L)	8.77 ± 0.70	8.93 ± 1.01
HOMA-index	1.97 ± 0.18	2.03 ± 0.26
Glycated haemoglobin (%)	5.1 ± 0.1	5.4 ± 0.1

Values are means±SEM. Abbreviations: BMI, Body Mass Index; HOMA-index, Homeostatic Model Assessment Index [75]

Table 2: Muscle fibre characteristics

		CON		NMES	
	Fibre type	Pre	Post	Pre	Post
Muscle fibre CSA (µm²)	I	5259 ± 328	5378 ± 392	5676 ± 424	5493 ± 430
	II	6680 ± 328 *	6316 ± 441	5885 ± 426	6412 ± 586 †
% Fibre (number)	I	43 ± 3	45 ± 4	52 ± 3	46 ± 3
	II	57 ± 3 *	55 ± 4	48 ± 3	54 ± 3
Nuclei per fibre	I	2.8 ± 0.2	2.9 ± 0.2	2.9 ± 0.2	2.7 ± 0.2
	II	3.3 ± 0.1	3.3 ± 0.2	2.9 ± 0.2	2.9 ± 0.2
Myonuclear domain (µm²)	I	1910 ± 57	1848 ± 68	1944 ± 87	1997 ± 63
	II	2057 ± 103 *	1935 ± 79	2004 ± 89	2233 ± 83 #
Number of SCs per fibre	I	0.090 ± 0.007	0.109 ± 0.009	0.115 ± 0.011	0.106 ± 0.010
	II	0.072 ± 0.006	0.075 ± 0.007	0.075 ± 0.011 *	0.060 ± 0.007
Number of SCs per mm²	I	17.3 ± 0.3	20.8 ± 1.7	20.8 ± 2.0	19.2 ± 1.4
	II	11.5 ± 1.4 *	12.5 ± 1.6	12.5 ± 1.4 *	9.6 ± 1.0
SCs/myonuclei (%)	I	3.3 ± 0.2	3.8 ± 0.3	4.0 ± 0.4	3.8 ± 0.3
	II	2.2 ± 0.2 *	2.4 ± 0.3	2.5 ± 0.3 *	2.1 ± 0.2

Data represent means±SEM. Abbreviations: CSA, Cross sectional area; SC, satellite cell; SCs/myonuclei (%), the number of SCs as a percentage of the total number of myonuclei (i.e. number of myonuclei + number of SCs). * Significantly different from type I fibre value ($P<0.05$). † Significantly different from pre value in NMES group. # Significantly different from CON post-immobilisation value ($P<0.05$)

Figure legends

Figure 1: Schematic representation of the experimental protocol. NMES = Neuromuscular electrical stimulation

Figure 2: Cross-sectional area (CSA) of *m. quadriceps femoris* in the CON and NMES group, before and after 5 days of one-legged knee immobilisation, as measured by single-slice CT scan. Data were analysed with a Repeated Measures ANOVA, and demonstrated a significant time*treatment interaction (P=0.001). Data are expressed as means±SEM. * P<0.05; significantly different when compared with pre-immobilisation values.

Figure 3: Skeletal muscle mRNA expression of myostatin, MyoD and myogenin in the CON and NMES group before and after 5 days of one-legged knee immobilisation. Data were analysed with a Repeated Measures ANOVA, and expressed as means±SEM. * P<0.05; significantly different when compared with pre-immobilisation values.

Figure 4: Skeletal muscle mRNA expression of selected genes of interest in the CON and NMES group before and after 5 days of one-legged knee immobilisation. Data were analysed with a Repeated Measures ANOVA. * P<0.05; significantly different when compared with pre-immobilisation values. Data are expressed as means±SEM. Abbreviations: MAFbx, Muscle Atrophy F-box; MuRF1, Muscle RING-finger protein-1; FOXO1, Forkhead box protein O1; FAK, Focal Adhesion Kinase; LAT1, large neutral amino acid transporter 1; PAT1, Proton-coupled amino acid transporter 1.